ClinicalTrials.gg
RecruitingNCT07074028REAMUSUpdated Oct 26, 2026

Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for Sepsis

An interventional study of Medical Research Council sum score (MRC-SS) test and Handgrip test combined with surface electromyography (sEMG) in Sepsis and Myopathy Critical Illness, sponsored by Centre Hospitalier de Saint-Brieuc. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centre Hospitalier de Saint-Brieuc · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Sepsis with a site in France — 41 open to participants now, 46 under way, 5 of them phase 3. Sepsis · France.

Planned enrollment
76th of 111
63 · median 150
Started
2025
with 9 others
No phase
53 of 209
11 open now
Primary completion
2027-06
later than 26 of 45 live
Registered
190th of 209
by date

Among the 209 studies in Sepsis with a site in France, this one is the 76th largest by planned enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2025, is one of 53 with no phase, reaches primary completion later than 26 of the 45 other live ones, and was the 190th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

41 of the 209 studies in Sepsis with a site in France are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Sepsis with a site in France, or all of them as a file.
02

Study summary

Approximately 40% of patients develop muscle dysfunction during their stay in intensive care, particularly in the context of sepsis. This dysfunction represents an acquired muscle injury that is secondary to the primary illness that led to ICU admission. It affects both the limb muscles and the respiratory muscles of the thoracic cage. Clinically, this manifests as bilateral and symmetrical muscle weakness in the limbs, and contributes significantly to difficulties in weaning patients off mechanical ventilation.

The loss of muscle mass is directly correlated with the severity of the patient's clinical condition and can reach up to 20% of initial muscle mass within just ten days. This rapid and profound atrophy primarily results from an imbalance between increased muscle protein breakdown (catabolism) and insufficient protein synthesis (anabolism). The consequences of this muscle dysfunction are significant and far-reaching, with a marked negative impact on the overall prognosis.

This condition is associated with longer durations of mechanical ventilation and extended stays in the intensive care unit. Beyond the acute phase, patients often experience persistent reductions in physical performance, leading to long-term functional limitations that impair quality of life. Furthermore, ICU-acquired muscle dysfunction has been linked to increased long-term mortality, with excess deaths reported at both one year and five years following ICU discharge. This risk is especially pronounced when the muscle dysfunction is severe and continues beyond the hospitalization period.

Several risk factors for ICU-acquired muscle dysfunction may be modifiable, opening up the possibility for preventive or therapeutic interventions. Two main factors have been identified as particularly relevant: (1) the duration of immobility and muscular inactivity, and (2) the adequacy of nutritional support, especially regarding amino acid intake, which is critical for maintaining muscle protein synthesis.

In response to these factors, early and active mobilization of ICU patients has become a key component of recommended care, often in conjunction with strategies aimed at minimizing the use of sedative medications. These practices are encouraged by international guidelines, reflecting a growing consensus around the importance of maintaining some level of muscular activity even in critically ill patients. However, despite these recommendations, no definitive evidence has demonstrated a clear improvement in patient outcomes associated with early mobilization.

This lack of clear benefit may stem from multiple factors, including the variability in patient severity across clinical trials and, importantly, the timing of the intervention. The anabolic signals triggered by muscle contraction are only effective if they are strong enough to counterbalance the catabolic signals driven by inflammation, infection, or muscle hypoxia-all of which fluctuate over the course of illness and recovery.

Regarding nutritional interventions, the appropriate timing and quantity of calorie and protein intake necessary to support adequate anabolism and mitigate muscle loss remain controversial. Although amino acids are essential for muscle protein synthesis, current studies have not shown consistent improvements in muscle function based on different nutritional strategies in the ICU setting.

Given the high prevalence of ICU-acquired muscle dysfunction in patients with sepsis, its significant impact on outcomes, and the lack of an effective, evidence-based treatment, there is a pressing need to deepen our scientific understanding of this phenomenon. Improving knowledge in this area could lead to more targeted and effective interventions, ultimately helping to preserve muscle mass and function in critically ill patients and improving both their short- and long-term prognosis.

Read the detailed description

The care provided to participants enrolled in the study remains unchanged. Standard care is administered. In particular, there are no modifications to routine practices regarding early mobilization, physiotherapy, physical exercise, or nutritional management.

The muscular phenotype of enrolled participants is assessed longitudinally during their ICU stay and after hospital discharge. Several follow-up visits are scheduled:

  • Visit 1: Inclusion
  • Visit 2: Day 3 (D3)
  • Visit 3: Day 7 (D7)
  • Visit 4: Day 14 (D14)
  • Visit 5: Day 21 (D21)
  • Visit 6: Day 28 (D28)
  • Visit 7: ICU discharge (may occur before D28)
  • Visit 8: Day 90 (D90) - End of study

During these visits, the muscular phenotype is evaluated using non-invasive methods (clinical assessments, ultrasound imaging, and electroneuromyography). Blood samples are collected to determine the inflammatory status of participants and to assess dysfunctions in vital organs.

After the ICU stay, in addition to these data, participants' physical and functional autonomy is documented. Cognitive impairments and symptoms of anxiety and depression are also recorded, along with their nutritional status.

03

Conditions studied

  • Sepsis
  • Myopathy Critical Illness

Keywords

  • muscle atrophy
  • electromyography
  • Muscle Strength
  • conditioned medium with human serum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants admitted to ICU with an expected length of stay greater than 7 days.
  • Expected duration of invasive mechanical ventilation greater than 48 hours.
  • Diagnosis of sepsis upon ICU admission (presence of an infection and a SOFA score ≥ 2, or an increase of ≥ 2 points if organ dysfunction was present prior to infection).
  • obtained from the participant or from a designated surrogate decision-maker

Exclusion criteria

Exclusion Criteria:

  • Pregnant women.
  • Participants not affiliated with the national health insurance system.
  • Participants under legal protection (guardianship or conservatorship).
  • Moribund participants (end-of-life patients).
  • Participants with active cancer.
  • Participants with chronic neuromuscular disorders or admitted to the ICU for an acute neuromuscular condition.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Longitudinal characterization of muscle phenotype in ICU participants with sepsis

    Through successive visits during and after the ICU stay, the muscle phenotype of participants is determined using non-invasive data collection methods (clinical assessments, ultrasound imaging, and electroneuromyography). Blood samples are harvested to assess the participants' inflammatory status and evaluate organ dysfunction. Following the ICU stay, in addition to the previously mentioned data, participants' physical and functional autonomy is assessed. Cognitive impairments and symptoms of anxiety and depression are also recorded, along with their nutritional status.

    Diagnostic Test: Medical Research Council sum score (MRC-SS) test · Diagnostic Test: Handgrip test combined with surface electromyography (sEMG) · Diagnostic Test: Electrical activity during maximal voluntary contraction of the rectus femoris · Device: Musculoskeletal Ultrasound · Device: Diaphragmatic ultrasound · Biological: blood sampling · Device: Electroneuromyogram · Diagnostic Test: 6-minute walk test · Diagnostic Test: Montreal Cognitive Assessment (MoCA) · Behavioral: MNA-SF

Interventions

  • Diagnostic testMedical Research Council sum score (MRC-SS) test

    Medical Research Council (MRC)-sumscore evaluates global muscle strength. Manual strength of six muscle groups (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion) is evaluated on both sides using MRC scale

  • Diagnostic testHandgrip test combined with surface electromyography (sEMG)

    Handgrip test combined with surface electromyography (sEMG) of the flexor digitorum superficialis

  • Diagnostic testElectrical activity during maximal voluntary contraction of the rectus femoris

    Surface EMG amplitude (RMS) during maximal voluntary contraction measured by surface electromyography (sEMG) of the rectus femoris

  • DeviceMusculoskeletal Ultrasound

    Measurement of the cross-sectional area (CSA) of the rectus femoris by ultrasound

  • DeviceDiaphragmatic ultrasound

    Diaphragmatic ultrasound is a non-invasive technique that allows for sequential assessment of diaphragm mobility (excursion) and contraction (thickening) in mechanically ventilated patients

  • Biologicalblood sampling

    Blood samples are collected from a radial or femoral arterial catheter, which is part of the routine care of the patients. These samples are taken with the aim to: 1) describe the inflammatory profile (plasma measurements of CRP, IL-1, IL-6, TNFα, IL-10, fibrinogen, ferritin, cortisol), 2) assess organ dysfunction and calculate the SOFA score (arterial blood gases, lactate levels, liver function tests, complete blood count, and blood electrolyte panel)

  • DeviceElectroneuromyogram

    Analysis of peripheral neurogenic and myogenic components involved in intensive care unit-acquired muscle dysfunction through the performance of an electroneuromyogram

  • Diagnostic test6-minute walk test

    The 6-minute walk test (6MWT) is a simple test that requires a quiet, indoor, flat 30-meter course, ideally in a straight rectangular hallway

  • Diagnostic testMontreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is the most sensitive rapid assessment test and assesses cognitive functions most broadly (attention, concentration, executive functions, memory, language, visual-constructive abilities, abstraction, calculation, orientation).

  • BehavioralMNA-SF

    The MNA-SF (Short Form) is a simplified version that allows us to determine whether the elderly person is well nourished, at risk of malnutrition or malnourished.

06

What researchers measure

Primary outcomes

  1. MRC score (Medical Research Council).

    The MRC score allows for a global assessment of muscle function in ICU patients. An MRC score below 48, measured on day 28 or at ICU discharge (if discharge occurs before day 28), defines ICU-acquired weakness (ICU-AW).

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

Secondary outcomes

  1. Handgrip test combined with surface electromyography (sEMG)

    Handgrip test combined with surface electromyography (sEMG) of the flexor digitorum superficialis

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

  2. Electrical activity during maximal voluntary contraction of the rectus femoris

    Surface EMG amplitude (RMS) during maximal voluntary contraction measured by surface electromyography (sEMG) of the rectus femoris

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

  3. Musculoskeletal Ultrasound

    Measurement of the cross-sectional area (CSA) of the rectus femoris by ultrasound

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

  4. Diaphragmatic ultrasound

    Diaphragmatic ultrasound is a non-invasive technique that allows for sequential assessment of diaphragm mobility (excursion) and contraction (thickening) in mechanically ventilated patients

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

  5. Electroneuromyogram

    Analysis of peripheral neurogenic and myogenic components involved in intensive care unit-acquired muscle dysfunction through the performance of an electroneuromyogram

    Time frame: Only during the last visit of the protocol : 90 days after the inclusion

  6. Plasma concentrations of inflammation-related proteins

    Blood samples are collected from a radial or femoral arterial catheter, which is part of the routine care of the patients. These samples are taken with the aim to describe the plasma inflammatory profile including CRP, IL-1, IL-6, TNFα, IL-10, fibrinogen, ferritin and cortisol concentrations. All these data are reported in a Outcome Measure results data table.

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

  7. Organ dysfunction assesment

    Blood samples are collected from a radial or femoral arterial catheter, which is part of the routine care of the patients. These samples are taken with the aim to assess organ dysfunction and calculate the SOFA score (arterial blood gases, lactate levels, liver function tests, complete blood count, and blood electrolyte panel).

    Time frame: From enrollment to the end of the participant's study period (maximum 90 days)

  8. 6-minute walk test

    The 6-minute walk test (6MWT) is a simple test that requires a quiet, indoor, flat 30-meter course, ideally in a straight rectangular hallway

    Time frame: Only during the last visit of the protocol : 90 days after the inclusion

  9. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is the most sensitive rapid assessment test and assesses cognitive functions most broadly (attention, concentration, executive functions, memory, language, visual-constructive abilities, abstraction, calculation, orientation).

    Time frame: Only during the last visit of the protocole : 90 days after the inclusion

  10. MNA-SF

    The MNA-SF (Short Form) is a simplified version that allows us to determine whether the elderly person is well nourished, at risk of malnutrition or malnourished.

    Time frame: Only during the last visit of the protocol : 90 days after the inclusion

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier
    Saint-Brieuc, 22000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.

Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 27 months is above that.

Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 20, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Jun 25, 2027
CompletionEst.
Jun 25, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07074028
Lead sponsor
Centre Hospitalier de Saint-Brieuc
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Mar 25, 2025
Primary completion
Jun 25, 2027 (estimated)
Completion
Jun 25, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Nicolas BARBAROT
Contact
nicolas.barbarot@armorsante.bzh
+33(0)296017123
Frédéric DERBRE
Contact
frederic.derbre@univ-rennes2.fr
+33(0)290091588

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion